Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

被引:9
作者
Pan, Rui [1 ]
Cheng, Jinping [2 ]
Lai, Kelin [1 ]
Huang, Qing [3 ]
Wu, Hui [1 ]
Tang, Yamei [2 ]
机构
[1] Huizhou Hlth Sci Polytech, Dept Nursing, Huizhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huizhou Hlth Sci Polytech, Dept Basic Courses, Huizhou, Guangdong, Peoples R China
基金
国家重点研发计划;
关键词
Intracranial hemorrhage; Vitamin K antagonists; Prothrombin complex concentrate; Meta-analysis; FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; ANTICOAGULATION REVERSAL; WARFARIN; GUIDELINES; MANAGEMENT; COAGULOPATHY; ENLARGEMENT;
D O I
10.1007/s10072-019-3726-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Prothrombin complex concentrate (PCC) is the treatment of choice in vitamin K antagonist-associated intracranial hemorrhage (VKA-ICH). However, the efficiency and safety associated with their use remain unclear. Aims This study aimed to assess the current evidence of the clinical outcomes in patients with VKA-ICH treated with or without PCC. Summary of review A meta-analysis was conducted. Two randomized controlled trials and 19 observational studies were included. PCC use demonstrated a significant increased likelihood of international normalized ratio (INR) normalization (OR=3.76; 95% CI 1.74-8.12), shortened time to INR correction (MD=-1.30; 95% CI -2.08 to -0.53) and reduction of hematoma expansion (HE) rate (OR=0.37; 95% CI 0.23-0.60). Although PCC use revealed a statistical reduction at 30-day mortality (OR=0.62; 95% CI 0.50-0.78), the result was inconsistent with mortality at discharge (OR=1.03; 95% CI 0.68-1.57) and 90-day follow-up (OR=0.50; 95% CI 0.24-1.07), both of which yielded no significant difference. When subgroup analyses were performed focus on PCC only treatment with FFP, no statistically significant difference was observed in 30-day mortality (OR=0.43; 95% CI 0.11-1.71) as well. Besides, significant difference was not found in neurologic improvement at discharge (OR=1.85; 95% CI 0.32-10.75), 30-day follow-up (OR=3.00; 95% CI 0.93-9.70), or 90-day follow-up (OR=1.55; 95% CI 0.84-2.86). No statistically significant difference was noted in the risk of thromboembolism following PCC administration (OR=0.61; 95% CI 0.23-1.63). Conclusions PCC use for VKA-ICH reversal was associated with a significant reduction in INR and HE rate, without an increased risk of thromboembolic events. However, this reduction was not associated with improvement in neurologic deficits or overall survival. Well-designed randomized trials with special considerations to the aspect are necessary.
引用
收藏
页码:813 / 827
页数:15
相关论文
共 50 条
  • [21] Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis
    AlKherayf, Fahad
    Xu, Yan
    Gandara, Esteban
    Westwick, Harrison
    Moldovan, Ioana Doina
    Wells, Philip S.
    THROMBOSIS RESEARCH, 2016, 144 : 152 - 157
  • [22] Hemostasis Using Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: Systematic Review with Meta-Analysis
    Li, Jun-Ping
    Li, Van
    Li, Bing
    Bian, Chang-He
    Zhao, Feng
    BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY, 2024, 39 (02)
  • [23] Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists A meta-analysis
    Dentali, Francesco
    Marchesi, Chiara
    Pierfranceschi, Matteo Giorgi
    Crowther, Mark
    Garcia, David
    Hylek, Elaine
    Witt, Daniel M.
    Clark, Nathan P.
    Squizzato, Alessandro
    Imberti, Davide
    Ageno, Walter
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (03) : 429 - 438
  • [24] Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis
    Milioglou, Ioannis
    Farmakis, Ioannis
    Neudeker, Mandy
    Hussain, Zeeshan
    Guha, Avirup
    Giannakoulas, George
    Kotoula, Vassiliki
    Papaioannou, Maria
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 52 (04) : 1137 - 1150
  • [25] Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies
    Guo, Zongwen
    Ding, Xiaoli
    Ye, Zi
    Chen, Weiling
    Chen, Yijian
    CLINICAL CARDIOLOGY, 2021, 44 (07) : 917 - 924
  • [26] Risk Factors for Anticoagulant-Associated Intracranial Hemorrhage: A Systematic Review and Meta-analysis
    Zeng, Zhiwei
    Chen, Jiana
    Qian, Jiafen
    Ma, Fuxin
    Lv, Meina
    Zhang, Jinhua
    NEUROCRITICAL CARE, 2023, 38 (03) : 812 - 820
  • [27] Four-Factor Prothrombin Complex Concentrate Versus Plasma for Urgent Vitamin K Antagonist Reversal New Evidence
    Sarode, Ravi
    CLINICS IN LABORATORY MEDICINE, 2014, 34 (03) : 613 - +
  • [28] Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0
    Zemrak, Wesley R.
    Smith, Kathryn E.
    Rolfe, Stephen S.
    May, Teresa
    Trowbridge, Robert L.
    Hayes, Timothy L.
    Grindlinger, Gene A.
    Seder, David B.
    NEUROCRITICAL CARE, 2017, 27 (03) : 334 - 340
  • [29] A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy
    Khorsand, Nakisa
    Kooistra, Hilde A. M.
    van Hest, Reinier M.
    Veeger, Nic J. G. M.
    Meijer, Karina
    THROMBOSIS RESEARCH, 2015, 135 (01) : 9 - 19
  • [30] Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis
    DiRisio, Aislyn C.
    Harary, Maya
    Muskens, No S.
    Yunusa, Ismaeel
    Gormley, William B.
    Aglio, Linda S.
    Smith, Timothy R.
    Connors, Jean M.
    Mekary, Rania A.
    Broekman, Marike L. D.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 62 : 188 - 194